In August, OCRA hosted a listening session with the U.S. Food and Drug Administration (FDA) to better understand the impact of Covid-19 on clinical trial participation.
Watch the full FDA listening session in the video below.
Related Topics
(Upcoming Webinar) Ask the Experts: Gynecologic Clear Cell Carcinoma
Live webinar on March 25 will explore gynecologic clear cell carcinoma research, treatment, and survivorship Ovarian Cancer Research Alliance (OCRA) invites you to join our upcoming Ask the Experts webinar focused on gynecologic clear cell carcinoma, a rare subtype of gynecologic cancer. This live, interactive session will feature gynecologic oncologist Aaron Praiss, MD, who will discuss current research, treatment … Continued
OCRA Sponsors NCCN Guidelines for Cervical, Ovarian, and Uterine Cancer Patients
This article was updated in February 2026 to reflect NCCN’s release of the 2026 Guidelines for Cervical Cancer Patients. OCRA is a proud sponsor of the 2026 Patient Guidelines for Cervical Cancer, and the 2025 Patient Guidelines for Ovarian, and Uterine Cancer. We believe ensuring access to clear, understandable information is critical. NCCN provides wonderful … Continued
Global Ovarian Cancer Research Consortium Awards Inaugural AI Accelerator Grant with Microsoft’s AI for Good Lab
$1 million global research award, plus an additional $1 million in compute support, advances AI-driven efforts to personalize ovarian cancer care The Global Ovarian Cancer Research Consortium today awarded its inaugural AI Accelerator Grant to an international team of researchers to examine whether artificial intelligence (AI) can improve how survival and treatment response are predicted … Continued